SGEN Seagen Inc. Stock Quote

SGEN [NASD]

Index	-	P/E	43.92	EPS (ttm)	3.60	Insider Own	0.70%	Shs Outstand	181.63M	Perf Week	9.53%
Market Cap	27.50B	Forward P/E	1399.91	EPS next Y	0.11	Insider Trans	-15.74%	Shs Float	180.24M	Perf Month	0.58%
Income	660.70M	PEG	1.12	EPS next Q	-0.56	Inst Own	95.60%	Short Float	1.33%	Perf Quarter	16.15%
Sales	2.27B	P/S	12.10	EPS this Y	451.20%	Inst Trans	6.62%	Short Ratio	2.98	Perf Half Y	-4.73%
Book/sh	18.67	P/B	8.47	EPS next Y	105.50%	ROA	16.00%	Target Price	189.13	Perf Year	-6.42%
Cash/sh	14.10	P/C	11.22	EPS next 5Y	39.20%	ROE	19.00%	52W Range	133.20 - 213.94	Perf YTD	-9.68%
Dividend	-	P/FCF	36.36	EPS past 5Y	41.20%	ROI	17.10%	52W High	-24.73%	Beta	0.81
Dividend %	-	Quick Ratio	6.80	Sales past 5Y	45.20%	Gross Margin	88.90%	52W Low	20.89%	ATR	4.44
Employees	2092	Current Ratio	7.10	Sales Q/Q	39.70%	Oper. Margin	26.00%	RSI (14)	69.27	Volatility	3.47% 2.90%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-281.10%	Profit Margin	26.30%	Rel Volume	0.78	Prev Close	158.19
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Jul 29 AMC	Payout	0.00%	Avg Volume	804.44K	Price	161.03
Recom	2.20	SMA20	9.60%	SMA50	6.20%	SMA200	-0.30%	Volume	135,628	Change	1.80%

May-17-21

Initiated

Evercore ISI

In-line

Mar-31-21

Initiated

Credit Suisse

Neutral

$145

Feb-01-21

Downgrade

RBC Capital Mkts

Outperform → Sector Perform

$188 → $186

Jan-15-21

Upgrade

BofA Securities

Neutral → Buy

$215

Sep-22-20

Reiterated

Stifel

Hold

$145 → $165

Aug-24-20

Resumed

Berenberg

Buy

$187

Jul-31-20

Reiterated

H.C. Wainwright

Buy

$175 → $200

Jul-24-20

Downgrade

Piper Sandler

Overweight → Neutral

May-26-20

Initiated

JMP Securities

Mkt Outperform

$185

May-01-20

Upgrade

Guggenheim

Neutral → Buy

May-01-20

Reiterated

Needham

Buy

$157 → $163

Feb-18-20

Downgrade

Barclays

Overweight → Equal Weight

$124

Feb-12-20

Reiterated

H.C. Wainwright

Buy

$140 → $150

Feb-11-20

Reiterated

Goldman

Buy

$126 → $165

Jan-28-20

Initiated

BMO Capital Markets

Outperform

Jan-27-20

Initiated

BMO Capital Markets

Outperform

Jan-02-20

Downgrade

Guggenheim

Buy → Neutral

Dec-10-19

Initiated

Morgan Stanley

Equal-Weight

Dec-03-19

Resumed

BofA/Merrill

Neutral

Oct-22-19

Reiterated

H.C. Wainwright

Buy

$98 → $140

Jul-30-21 10:03AM	Seattle Genetics (SGEN) Q2 2021 Earnings Call Transcript Motley Fool
Jul-29-21 05:25PM	Seattle Genetics (SGEN) Reports Q2 Loss, Tops Revenue Estimates Zacks
04:02PM	Seagen Reports Second Quarter 2021 Financial Results Business Wire
Jul-22-21 03:03PM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release Zacks
Jul-09-21 02:10PM	U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer PR Newswire
02:10PM	U.S. FDA Grants Regular Approval and Expands Indication for PADCEV® (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer Business Wire
Jul-08-21 08:00AM	Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021 Business Wire
Jun-28-21 09:43AM	Hedge Funds Have Never Been This Bullish On Seagen Inc. (SGEN) Insider Monkey
Jun-16-21 06:38AM	Seagen Inc. (NASDAQ:SGEN) Shares Could Be 38% Below Their Intrinsic Value Estimate Simply Wall St.
Jun-03-21 06:00AM	Seagen Announces Long-Term Results from TUKYSA® (tucatinib) Pivotal Trial in Patients with HER2-Positive Breast Cancer During the Virtual Scientific Program of the 2021 ASCO Annual Meeting Business Wire
Jun-02-21 08:00AM	Seagen to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference Business Wire
May-25-21 01:12PM	Top Healthcare Stocks for June 2021 Investopedia
May-19-21 05:00PM	Seagen and Astellas Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy Business Wire
05:00PM	Astellas and Seagen Announce Updated Results from Two Trials of PADCEV® (enfortumab vedotin-ejfv) in Patients with Locally Advanced or Metastatic Urothelial Cancer Not Eligible for Cisplatin Chemotherapy PR Newswire
Apr-30-21 03:01AM	Seattle Genetics (SGEN) Q1 2021 Earnings Call Transcript Motley Fool
Apr-29-21 05:25PM	Seattle Genetics (SGEN) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:02PM	Seagen Reports First Quarter 2021 Financial Results Business Wire
02:30PM	Seagen Inc. to Host Earnings Call ACCESSWIRE
08:00AM	Seagen to Showcase Data from Growing Oncology Portfolio During Virtual Scientific Program of the 2021 ASCO Annual Meeting Business Wire
Apr-22-21 12:33PM	Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know Zacks
Apr-19-21 08:00AM	Seagen and Astellas Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM	Astellas and Seagen Announce U.S. FDA Acceptance of Two Supplemental Biologics License Applications for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Apr-16-21 07:07AM	Is Weakness In Seagen Inc. (NASDAQ:SGEN) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? Simply Wall St.
Apr-09-21 04:00PM	Seagen and Genmab Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Business Wire
04:00PM	Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer Business Wire
08:00AM	Seagen to Highlight Data from Novel Targeted Therapies at AACR Business Wire
Apr-07-21 08:00AM	Seagen to Host Conference Call and Webcast Discussion of First Quarter 2021 Financial Results on April 29, 2021 Business Wire
Mar-26-21 02:00AM	European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin Business Wire
Mar-18-21 06:02PM	Top Biotech Stocks for Q2 2021 Investopedia
Mar-13-21 10:30AM	Seattle Genetics (SGEN) Down 12.4% Since Last Earnings Report: Can It Rebound? Zacks
Mar-05-21 08:00AM	Seagen Recommends Rejection Of 'Mini-Tender' Offer from TRC Capital Investment Corporation Business Wire
Feb-27-21 09:23AM	15 Fastest Growing Biotech Companies in the US Insider Monkey
Feb-24-21 08:00AM	Seagen to Present at the Cowen 41st Annual Healthcare Conference Business Wire
Feb-18-21 08:00AM	Seagen and Astellas Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer Business Wire
08:00AM	Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV® (enfortumab vedotin-ejfv) in Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Feb-15-21 05:41AM	Announcing: Seagen (NASDAQ:SGEN) Stock Soared An Exciting 445% In The Last Five Years Simply Wall St.
Feb-12-21 02:15PM	Seagen and Astellas Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy Business Wire
02:15PM	Seagen and Astellas Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer Business Wire
02:15PM	Astellas and Seagen Announce Presentation of Results from PADCEV® (enfortumab vedotin-ejfv) Pivotal Trial in Patients with Previously Treated Advanced Urothelial Cancer Who Were Ineligible for Cisplatin Chemotherapy PR Newswire
02:15PM	Astellas and Seagen Announce Phase 3 Trial Results Demonstrating Survival Advantage of PADCEV® (enfortumab vedotin-ejfv) in Patients with Previously Treated Advanced Urothelial Cancer PR Newswire
10:28AM	Seagen (SGEN) Q4 Earnings Beat Estimates, Revenues Rise Y/Y Zacks
06:45AM	European Commission Approves Seagens TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
05:31AM	Seattle Genetics (SGEN) Q4 2020 Earnings Call Transcript Motley Fool
Feb-11-21 05:45PM	Seattle Genetics (SGEN) Q4 Earnings and Revenues Top Estimates Zacks
04:02PM	Seagen Reports Fourth Quarter and Full Year 2020 Financial Results Business Wire
02:30PM	Seagen Inc. to Host Earnings Call ACCESSWIRE
Feb-10-21 04:05PM	Seagen and Genmab Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer Business Wire
Jan-07-21 08:00AM	Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2020 Financial Results on February 11, 2021 Business Wire +5.76%
Dec-30-20 12:04PM	Merck Had a Disappointing 2020. Why Its Strategy Could Pay Off in 2021. Barrons.com
Dec-16-20 08:00AM	Seagen to Present at the J.P. Morgan Healthcare Conference Business Wire
03:18AM	Is Seagen Inc. (NASDAQ:SGEN) Popular Amongst Institutions? Simply Wall St.
Dec-11-20 07:23AM	Seagen Announces Positive CHMP Opinion for TUKYSA® (tucatinib) for the Treatment of Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer Business Wire
Dec-08-20 08:00AM	Seagen Highlights TUKYSA® (tucatinib) Data in Breast Cancer at Virtual 2020 San Antonio Breast Cancer Symposium Business Wire
Dec-07-20 10:00AM	Seagen Announces Multiple ADCETRIS® (brentuximab vedotin) Presentations at the 2020 ASH Annual Meeting Business Wire
Nov-11-20 03:15AM	These 23 stocks and ETFs will benefit from the 6 most important changes for stock-market investors under Biden MarketWatch
Nov-09-20 08:00AM	Seagen Highlights Immuno-Oncology Data from Broad Portfolio During SITC Virtual Annual Meeting 2020 Business Wire
Nov-05-20 08:00AM	Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting Business Wire
Nov-03-20 08:57AM	Were Hedge Funds Right About Warming Up To Seagen Inc. (SGEN)? Insider Monkey
06:17AM	Seagen Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions Simply Wall St.
Nov-02-20 08:00AM	Seagen to Host Virtual R&D Day on November 16, 2020 Business Wire
Oct-30-20 01:07PM	Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut Zacks -13.28%
06:01AM	Seattle Genetics (SGEN) Q3 2020 Earnings Call Transcript Motley Fool
Oct-29-20 06:05PM	Seattle Genetics (SGEN) Q3 Earnings and Revenues Top Estimates Zacks
04:02PM	Seagen Reports Third Quarter 2020 Financial Results Business Wire
Oct-28-20 08:00AM	Seagen Announces Closing of $1.0 Billion Stock Sale to Merck Business Wire
Oct-22-20 12:33PM	Seattle Genetics (SGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release Zacks
12:27PM	Are Investors Undervaluing Seagen Inc. (NASDAQ:SGEN) By 21%? Simply Wall St.
Oct-13-20 01:33PM	Seagen Posts Upbeat Top-Line Data From EV-201 Study on Padcev Zacks
08:00AM	Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2020 Financial Results on October 29, 2020 Business Wire
Oct-12-20 06:45AM	Seagen and Astellas Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer Business Wire
06:45AM	Astellas and Seagen Announce Positive Topline Results from Second Cohort of Patients in Phase 2 Pivotal Trial of PADCEV® (enfortumab vedotin-ejfv) in Advanced Urothelial Cancer PR Newswire
Oct-08-20 08:00AM	Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc. Business Wire
Oct-07-20 09:44AM	Why Seattle Genetics Stock Jumped 24% in September Motley Fool
Oct-05-20 11:13AM	Does 'Aggressive' Bristol-Myers Have the Right Prescription for Investors? TheStreet.com
Oct-03-20 06:55AM	Next Coronavirus Market Crash: Where to Invest $10,000 Motley Fool
Oct-01-20 12:42PM	Seattle Genetics Hits New Highs and a Strategy Adjustment Is Needed TheStreet.com
Sep-28-20 05:33PM	Dow Jones Futures: Stock Market Rally Needs To Turn Up The Volume; Target, Adobe, Nvidia Lead Top Stocks In Buy Zones Investor's Business Daily
Sep-24-20 07:33AM	Seattle Genetics' Shares March Higher, Can It Continue? Zacks
Sep-21-20 10:20AM	Seattle Genetics and Genmab Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020 Business Wire
Sep-18-20 01:17PM	Seattle Genetics' Padcev Study Aids Urothelial Cancer Survival Zacks
12:38PM	Pharma Stock Roundup: AZN, LLY & PFE's Coronavirus Updates, MRK's New Cancer Deals Zacks
06:45AM	Seattle Genetics and Astellas Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer Business Wire
06:45AM	Astellas and Seattle Genetics Announce PADCEV® (enfortumab vedotin-ejfv) Significantly Improved Overall Survival in Phase 3 Trial in Previously Treated Locally Advanced or Metastatic Urothelial Cancer PR Newswire
Sep-16-20 10:09AM	Analysts Just Published A Bright New Outlook For Seattle Genetics, Inc.'s (NASDAQ:SGEN) Simply Wall St.
09:47AM	Biotech Stock Roundup: GILD to Buy IMMU, SGEN Collaborates With Merck & More Zacks
Sep-15-20 12:53PM	Seattle Genetics Up on Two New Oncology Deals With Merck Zacks
09:51AM	Merck Buys Rights to Co-Develop Seattle Genetics ADC Drug Zacks
Sep-14-20 07:01PM	Jim Cramer: Is This Market Undervalued? TheStreet.com +14.55%
05:40PM	Merck Inks Multibillion-Dollar Deal With Seattle Genetics, Including Equity Motley Fool
04:39PM	Seattle Genetics Pact With Drug Giant Merck Sends SGEN Stock Soaring Investor's Business Daily
04:34PM	US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes Reuters
04:00PM	US STOCKS-Wall Street closes broadly higher on deal news, vaccine hopes Reuters
03:55PM	Analyst Report: Seattle Genetics, Inc. Morningstar Research
01:41PM	Merck To Buy $1B Seattle Genetics Stake For Oncology Collab SmarterAnalyst
12:48PM	US STOCKS-Wall Street climbs on mega mergers, vaccine hopes Reuters
11:15AM	Mercks Partnership With Seattle Genetics Is a Bet on a New Anticancer Strategy Barrons.com
10:30AM	How About That Merck and Seattle Genetics Deal? TheStreet.com
09:55AM	Merck Inks Up to $4.5 Billion Seattle Genetics Cancer Deal Bloomberg
09:51AM	Looking Into Seattle Genetics's Return On Capital Employed Benzinga
09:45AM	Dow Jones Today, Stocks Open Higher On Nvidia, Gilead, Oracle Merger News; Micron Pops On Upgrade Investor's Business Daily

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of metastatic urothelial cancers; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. It also develops Tisotumab Vedotin for metastatic cervical cancer and other solid tumors; ladiratuzumab vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; and SEA-CD40, SEA-TGT, SEA-BCMA, and SEA-CD70 for various cancer diseases. Seagen Inc. has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and SpringWorks Therapeutics, Inc. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SIEGALL CLAY B	President and CEO	Jul 02	Option Exercise	15.46	15,268	236,043	722,621	Jul 06 09:40 PM
ROMP CHARLES R	EVP, Commercial	Jul 02	Sale	158.41	703	111,362	43,187	Jul 06 08:13 PM
SIEGALL CLAY B	President and CEO	Jul 02	Sale	156.36	15,268	2,387,233	715,209	Jul 06 09:40 PM
SIEGALL CLAY B	President and CEO	Jul 01	Option Exercise	15.46	14,085	217,754	721,374	Jul 06 09:40 PM
SIEGALL CLAY B	President and CEO	Jul 01	Sale	157.78	14,085	2,222,376	715,209	Jul 06 09:40 PM
DANSEY ROGER D	Chief Medical Officer	Jun 16	Sale	152.22	25,109	3,822,034	84,435	Jun 21 06:02 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 07	Option Exercise	26.10	1,303	34,008	54,315	Jun 08 08:50 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 07	Sale	150.00	1,303	195,450	53,012	Jun 08 08:50 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 03	Option Exercise	15.46	10,697	165,376	63,709	Jun 04 08:21 PM
SIEGALL CLAY B	President and CEO	Jun 03	Option Exercise	15.46	29,353	453,797	723,884	Jun 04 08:22 PM
SIEGALL CLAY B	President and CEO	Jun 03	Sale	144.51	29,353	4,241,801	715,209	Jun 04 08:22 PM
HIMES VAUGHN B	Chief Technical Officer	Jun 03	Sale	144.91	10,697	1,550,090	53,012	Jun 04 08:21 PM
ROMP CHARLES R	EVP, Commercial	May 17	Sale	145.95	334	48,746	43,890	May 19 07:10 PM
BAKER BROS. ADVISORS LP	Director	May 14	Option Exercise	19.02	35,000	665,700	43,307,671	May 18 04:23 PM
LIU JEAN I	GC/EVP, Leg Affairs	May 11	Sale	140.00	1,061	148,540	64,051	May 13 07:17 PM
SIEGALL CLAY B	President and CEO	May 06	Option Exercise	15.46	29,353	453,797	733,288	May 07 06:29 PM
SIEGALL CLAY B	President and CEO	May 06	Sale	134.97	29,353	3,961,824	715,209	May 07 06:29 PM
SIEGALL CLAY B	President and CEO	Apr 09	Option Exercise	15.46	12,602	194,827	721,310	Apr 09 08:13 PM
SIEGALL CLAY B	President and CEO	Apr 09	Sale	141.96	12,602	1,788,924	715,209	Apr 09 08:13 PM
SIEGALL CLAY B	President and CEO	Apr 08	Option Exercise	15.46	16,751	258,970	724,376	Apr 09 08:13 PM
SIEGALL CLAY B	President and CEO	Apr 08	Sale	145.17	16,751	2,431,816	715,209	Apr 09 08:13 PM
SIEGALL CLAY B	President and CEO	Mar 04	Option Exercise	15.46	29,353	453,797	726,618	Mar 05 07:56 PM
SIEGALL CLAY B	President and CEO	Mar 04	Sale	145.74	29,353	4,277,763	715,209	Mar 05 07:56 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 02	Option Exercise	15.46	12,000	185,520	141,889	Mar 04 07:27 PM
HIMES VAUGHN B	Chief Technical Officer	Mar 02	Sale	153.22	12,000	1,838,623	129,889	Mar 04 07:27 PM
LIU JEAN I	GC/EVP, Leg Affairs	Feb 17	Option Exercise	41.37	4,846	200,466	65,112	Feb 18 08:48 PM
SIEGALL CLAY B	President and CEO	Feb 04	Option Exercise	15.46	29,353	453,797	726,706	Feb 05 08:00 PM
SIEGALL CLAY B	President and CEO	Feb 04	Sale	165.57	29,353	4,860,105	715,209	Feb 05 08:00 PM
LIU JEAN I	GC/EVP, Leg Affairs	Jan 15	Option Exercise	35.95	5,000	179,750	65,266	Jan 15 07:40 PM
LIU JEAN I	GC/EVP, Leg Affairs	Jan 15	Sale	180.00	5,000	900,000	60,266	Jan 15 07:40 PM
SIEGALL CLAY B	President and CEO	Jan 07	Option Exercise	15.46	29,353	453,797	719,687	Jan 08 07:52 PM
SIEGALL CLAY B	President and CEO	Jan 07	Sale	172.44	29,353	5,061,681	715,209	Jan 08 07:52 PM
SIMPSON TODD E	Chief Financial Officer	Dec 18	Option Exercise	26.71	34,773	928,772	152,436	Dec 18 08:51 PM
SIMPSON TODD E	Chief Financial Officer	Dec 18	Sale	200.00	33,669	6,733,800	118,767	Dec 18 08:51 PM
LIU JEAN I	GC/EVP, Leg Affairs	Dec 16	Option Exercise	35.95	1,624	58,383	60,266	Dec 16 07:41 PM
LIU JEAN I	GC/EVP, Leg Affairs	Dec 14	Option Exercise	35.95	5,000	179,750	63,642	Dec 16 07:41 PM
LIU JEAN I	GC/EVP, Leg Affairs	Dec 14	Sale	195.86	5,000	979,316	58,642	Dec 16 07:41 PM
SIEGALL CLAY B	President and CEO	Dec 07	Option Exercise	15.46	15,723	243,078	720,265	Dec 08 07:33 PM
HIMES VAUGHN B	Chief Technical Officer	Dec 07	Option Exercise	25.36	12,761	323,646	199,590	Dec 09 08:08 PM
HIMES VAUGHN B	Chief Technical Officer	Dec 07	Sale	181.76	8,000	1,454,041	191,590	Dec 09 08:08 PM
SIEGALL CLAY B	President and CEO	Dec 07	Sale	181.14	15,723	2,848,122	715,209	Dec 08 07:33 PM
SIEGALL CLAY B	President and CEO	Dec 04	Option Exercise	15.46	21,732	335,977	730,117	Dec 08 07:33 PM
SIEGALL CLAY B	President and CEO	Dec 04	Sale	179.43	21,732	3,899,386	715,209	Dec 08 07:33 PM
SIEGALL CLAY B	President and CEO	Dec 03	Option Exercise	15.46	21,253	328,571	726,145	Dec 04 07:18 PM
ROMP CHARLES R	EVP, Commercial	Dec 03	Option Exercise	39.15	7,666	300,124	51,743	Dec 03 05:45 PM
ROMP CHARLES R	EVP, Commercial	Dec 03	Sale	179.30	7,666	1,374,514	44,077	Dec 03 05:45 PM
SIEGALL CLAY B	President and CEO	Dec 03	Sale	179.28	21,253	3,810,144	715,209	Dec 04 07:18 PM
ROMP CHARLES R	EVP, Commercial	Dec 01	Option Exercise	39.15	6,000	234,900	50,077	Dec 03 05:45 PM
ROMP CHARLES R	EVP, Commercial	Dec 01	Sale	179.09	6,000	1,074,539	44,077	Dec 03 05:45 PM
GRYSKA DAVID W	Director	Nov 19	Option Exercise	19.02	15,000	285,300	52,719	Nov 23 08:11 PM
GRYSKA DAVID W	Director	Nov 19	Sale	173.70	15,000	2,605,523	44,848	Nov 23 08:11 PM
SIMPSON TODD E	Chief Financial Officer	Nov 05	Sale	180.37	7,509	1,354,383	118,767	Nov 09 07:25 PM
GRYSKA DAVID W	Director	Nov 05	Sale	180.60	4,500	812,699	44,848	Nov 06 07:53 PM
ROMP CHARLES R	EVP, Commercial	Nov 04	Option Exercise	41.74	14,079	587,703	49,228	Nov 06 07:34 PM
ROMP CHARLES R	EVP, Commercial	Nov 04	Sale	180.37	14,079	2,539,420	44,077	Nov 06 07:34 PM
DANSEY ROGER D	Chief Medical Officer	Nov 04	Sale	177.00	7,661	1,356,020	110,221	Nov 05 09:38 PM
ROMP CHARLES R	EVP, Commercial	Nov 03	Option Exercise	19.24	5,197	99,979	47,719	Nov 04 08:23 PM
LIPPMAN MARC E	Director	Nov 03	Option Exercise	35.47	62,780	2,226,870	144,432	Nov 05 08:44 PM
LIPPMAN MARC E	Director	Nov 03	Sale	168.61	142,090	23,958,287	52,338	Nov 05 08:44 PM
ROMP CHARLES R	EVP, Commercial	Nov 03	Sale	172.07	6,061	1,042,939	44,077	Nov 04 08:23 PM
WELCH DANIEL G	Director	Nov 02	Option Exercise	25.21	49,500	1,247,652	71,098	Nov 04 08:51 PM
WELCH DANIEL G	Director	Nov 02	Sale	166.13	58,750	9,760,260	47,348	Nov 04 08:51 PM
ROMP CHARLES R	EVP, Commercial	Nov 02	Sale	166.77	13,001	2,168,129	44,941	Nov 04 08:23 PM
LIU JEAN I	GC/EVP, Leg Affairs	Sep 21	Option Exercise	36.77	9,954	366,019	58,642	Sep 23 07:28 PM
LIU JEAN I	GC/EVP, Leg Affairs	Sep 14	Sale	170.00	11,610	1,973,700	48,688	Sep 16 06:53 PM
HIMES VAUGHN B	Chief Technical Officer	Sep 09	Option Exercise	15.46	8,000	123,680	194,829	Sep 11 06:25 PM
HIMES VAUGHN B	Chief Technical Officer	Sep 09	Sale	147.55	8,000	1,180,385	186,829	Sep 11 06:25 PM
SIMPSON TODD E	Chief Financial Officer	Sep 01	Sale	155.86	12,091	1,884,512	126,276	Sep 02 07:24 PM
DANSEY ROGER D	Chief Medical Officer	Aug 31	Sale	155.69	4,611	717,906	117,882	Sep 02 07:25 PM
SIEGALL CLAY B	President and CEO	Aug 31	Sale	155.69	14,351	2,234,367	715,209	Sep 02 07:24 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 31	Sale	155.69	3,585	558,164	186,829	Sep 02 07:25 PM
SIMPSON TODD E	Chief Financial Officer	Aug 31	Sale	155.69	4,187	651,892	138,367	Sep 02 07:24 PM
ROMP CHARLES R	EVP, Commercial	Aug 31	Sale	155.69	1,133	176,402	57,942	Sep 02 07:25 PM
LIU JEAN I	GC/EVP, Leg Affairs	Aug 31	Sale	155.69	3,648	567,972	60,298	Sep 02 07:25 PM
SIEGALL CLAY B	President and CEO	Aug 21	Option Exercise	19.42	10,299	199,984	729,560	Aug 25 06:35 PM
LIU JEAN I	GC/EVP, Leg Affairs	Aug 18	Sale	158.17	6,846	1,082,823	63,946	Aug 20 06:58 PM
ROMP CHARLES R	EVP, Commercial	Aug 18	Sale	158.17	4,027	636,941	59,075	Aug 20 06:26 PM
SIEGALL CLAY B	President and CEO	Aug 18	Sale	158.17	27,060	4,280,053	719,261	Aug 20 06:26 PM
SIMPSON TODD E	Chief Financial Officer	Aug 18	Sale	158.17	9,262	1,464,959	142,554	Aug 20 06:27 PM
HIMES VAUGHN B	Chief Technical Officer	Aug 18	Sale	158.17	8,054	1,273,892	190,414	Aug 20 06:23 PM
DANSEY ROGER D	Chief Medical Officer	Aug 17	Sale	157.79	450	71,006	122,493	Aug 17 09:40 PM
SIEGALL CLAY B	President and CEO	Aug 10	Option Exercise	12.00	28,475	341,700	729,955	Aug 13 06:04 AM
SIEGALL CLAY B	President and CEO	Aug 10	Sale	156.74	28,475	4,463,263	718,339	Aug 13 06:04 AM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience